CGIM
ONC

Cannon Global Investment Management’s BeOne Medicines Ltd ONC Stock Holding History

Cannon Global Investment Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-600
Closed -$206K – 80
2021
Q2 		$206K Buy
+600
New +$199K 0.4% 35

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Cannon Global Investment Management's ONC Position: Q3 2021 in Review

Cannon Global Investment Management sold out of BeOne Medicines Ltd (ONC) in Q3 2021, closing a stake of 600 shares — an estimated $206K sold.

Cannon Global Investment Management first reported a position in ONC in Q2 2021 and held it in 1 quarter. The position peaked at $206K in Q2 2021. 254 funds tracked by Wall St. Rank hold ONC as of Q3 2021.

  • Cannon Global Investment Management reported no remaining BeOne Medicines Ltd position as of Q3 2021 after selling out during the quarter.
  • Cannon Global Investment Management sold 600 BeOne Medicines Ltd shares in Q3 2021, an estimated $206K.
  • Cannon Global Investment Management first reported a position in BeOne Medicines Ltd in Q2 2021 and held it in 1 quarter.
  • Cannon Global Investment Management's BeOne Medicines Ltd position peaked at $206K in Q2 2021.
  • 254 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2021.

Based on Cannon Global Investment Management's 13F filing for Q3 2021, filed 27 Oct 2021.